Endoscopic Retrograde Cholangiopancreatography ERCP

Endoscopic retrograde cholangiopancreatography (ERCP) carries a substantial risk of postprocedure pancreatitis (overall > 5% in prospective trials but as high as > 20% in subgroups of patients). The experience at the University of Louisville is somewhat less at 1.5%. A large number of studies have evaluated various medications administered before ERCP in an effort to minimize the risk of post-ERCP pancreatitis, but to date most have been found to be ineffective. A relatively small trial of 62 patients, found that volume expansion with 10% Dextran-40 at a dose of 3 mL/kg before ERCP led to a decrease in serum amylase but did not significantly effect post-ERCP pancreatitis.

0 0

Post a comment